ATE244888T1 - Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy - Google Patents
Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapyInfo
- Publication number
- ATE244888T1 ATE244888T1 AT94907439T AT94907439T ATE244888T1 AT E244888 T1 ATE244888 T1 AT E244888T1 AT 94907439 T AT94907439 T AT 94907439T AT 94907439 T AT94907439 T AT 94907439T AT E244888 T1 ATE244888 T1 AT E244888T1
- Authority
- AT
- Austria
- Prior art keywords
- hca
- generally
- human
- antibodies
- immunoassays
- Prior art date
Links
- 201000009030 Carcinoma Diseases 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 238000003018 immunoassay Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 abstract 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 abstract 2
- 150000001720 carbohydrates Chemical group 0.000 abstract 2
- 229930182830 galactose Natural products 0.000 abstract 2
- 210000005260 human cell Anatomy 0.000 abstract 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 abstract 2
- 101001133088 Homo sapiens Mucin-21 Proteins 0.000 abstract 1
- 102100034260 Mucin-21 Human genes 0.000 abstract 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Chemical group CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000011503 in vivo imaging Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Optics & Photonics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1445093A | 1993-02-05 | 1993-02-05 | |
| PCT/US1994/001379 WO1994018562A1 (en) | 1993-02-05 | 1994-02-07 | Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE244888T1 true ATE244888T1 (de) | 2003-07-15 |
Family
ID=21765551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94907439T ATE244888T1 (de) | 1993-02-05 | 1994-02-07 | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US5545532A (de) |
| EP (1) | EP0686260B1 (de) |
| JP (1) | JP4122050B2 (de) |
| AT (1) | ATE244888T1 (de) |
| AU (1) | AU6102494A (de) |
| CA (1) | CA2154266A1 (de) |
| DE (1) | DE69432926T2 (de) |
| WO (1) | WO1994018562A1 (de) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008090A1 (en) * | 1995-06-06 | 1998-02-26 | Epigen, Inc. | Anti-idiotypic antibodies to an epiglycanin |
| US6418338B1 (en) * | 1998-02-06 | 2002-07-09 | Phylatron Ltd. | Method for detecting and surgically removing lymphoid tissue involved in tumor progression |
| GB9806104D0 (en) * | 1998-03-20 | 1998-05-20 | Smithkline Beecham Biolog | Novel compounds |
| US6657048B2 (en) * | 1999-10-08 | 2003-12-02 | Arius Research, Inc. | Individualized anti-cancer antibodies |
| US6794494B1 (en) | 2003-04-14 | 2004-09-21 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8071072B2 (en) * | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| US7252821B2 (en) | 1999-10-08 | 2007-08-07 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US20040105816A1 (en) * | 1999-10-08 | 2004-06-03 | Young David S. F. | Cancerous disease modifying antibodies |
| US20080124327A1 (en) * | 1999-10-08 | 2008-05-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7256271B2 (en) | 2003-01-21 | 2007-08-14 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US20040001789A1 (en) * | 1999-10-08 | 2004-01-01 | Young David S. F. | Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof |
| US7419792B2 (en) * | 1999-10-08 | 2008-09-02 | Arius Research Inc. | Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody |
| US20090004103A1 (en) * | 1999-10-08 | 2009-01-01 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) * | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8048416B2 (en) * | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
| US6471968B1 (en) | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
| US6892140B1 (en) * | 2000-11-27 | 2005-05-10 | Enteron, Inc. | Immunogenic cancer peptides and uses thereof |
| US7534429B2 (en) * | 2000-11-29 | 2009-05-19 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US20060210474A1 (en) * | 2000-11-29 | 2006-09-21 | Young David S | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7009040B2 (en) * | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US7442777B2 (en) * | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7431923B2 (en) * | 2005-01-03 | 2008-10-07 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| US7951061B2 (en) * | 2001-07-25 | 2011-05-31 | Allan Foreman | Devices for targeted delivery of thermotherapy, and methods related thereto |
| EP2272946B9 (de) | 2002-02-25 | 2015-06-24 | Vaxiion Therapeutics, LLC | Minizell-Zusammensetzungen und Verfahren |
| US6949629B2 (en) * | 2002-03-13 | 2005-09-27 | Aspenbio, Inc. | Methods for purifying selected CEA family member proteins |
| WO2003105908A2 (en) * | 2002-03-15 | 2003-12-24 | Department Of Veterans Affairs, Rehabilitation R & D Service | Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| CN1711475A (zh) * | 2002-10-10 | 2005-12-21 | 退伍军人事务部 | 利用已标记的、针对肿瘤特异性表位的活化淋巴细胞进行肿瘤的检测、定位和分级 |
| US7468254B2 (en) * | 2003-01-21 | 2008-12-23 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| US7488475B2 (en) | 2003-01-21 | 2009-02-10 | Arius Research, Inc. | Antibody therapy of tumors |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| US7361342B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US7175846B2 (en) * | 2003-01-21 | 2007-02-13 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US7399835B2 (en) * | 2004-02-26 | 2008-07-15 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US7195764B2 (en) | 2003-04-14 | 2007-03-27 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US20080025977A1 (en) * | 2003-04-14 | 2008-01-31 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| US20080213169A1 (en) * | 2003-04-14 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| US20060140963A1 (en) * | 2003-04-14 | 2006-06-29 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD59 |
| US20050027106A1 (en) * | 2003-07-28 | 2005-02-03 | Young David S. F. | Cancerous disease modifying antibodies |
| US7348413B2 (en) * | 2004-02-26 | 2008-03-25 | Arius Research Inc. | Cancerous disease modifying antibodies |
| WO2005115477A2 (en) * | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Non-natural ribonuclease conjugates as cytotoxic agents |
| WO2005114202A2 (en) * | 2004-05-12 | 2005-12-01 | Egenix, Inc. | Method for diagnosis of prostate cancer |
| US20050255041A1 (en) * | 2004-05-13 | 2005-11-17 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| JP2008510829A (ja) * | 2004-08-25 | 2008-04-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | デンドリマーに基づく組成物およびそれらの使用法 |
| ATE476449T1 (de) * | 2004-12-03 | 2010-08-15 | Morphotek Inc | Verwendung von endosialinbindenden proteinen zum isolieren endosialinpositiver zellen |
| WO2006116451A2 (en) | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in endosialin-positive cells |
| US7452978B2 (en) * | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US7452979B2 (en) | 2005-08-02 | 2008-11-18 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US7456258B2 (en) | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US7494648B2 (en) * | 2005-08-02 | 2009-02-24 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| US7456259B2 (en) | 2005-08-02 | 2008-11-25 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| US20070041934A1 (en) * | 2005-08-12 | 2007-02-22 | Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
| US20080213267A1 (en) * | 2006-02-24 | 2008-09-04 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| CN101675158A (zh) * | 2006-02-24 | 2010-03-17 | 阿里乌斯研究公司 | 癌性疾病调节抗体 |
| US20080305104A1 (en) * | 2006-02-24 | 2008-12-11 | Young David S F | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US7420041B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2007095745A1 (en) | 2006-02-24 | 2007-08-30 | Arius Research Inc. | Cancerous disease modifying antibody 141205-02 |
| US8840882B2 (en) * | 2006-06-23 | 2014-09-23 | Quintessence Biosciences, Inc. | Modified ribonucleases |
| WO2008010991A2 (en) * | 2006-07-17 | 2008-01-24 | Quintessence Biosciences, Inc. | Methods and compositions for the treatment of cancer |
| US20080089891A1 (en) * | 2006-07-26 | 2008-04-17 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| CN101535471B (zh) * | 2006-11-13 | 2011-06-29 | 霍夫曼-拉罗奇有限公司 | 修饰癌症病的抗体180706-02 |
| KR20090088879A (ko) * | 2006-11-13 | 2009-08-20 | 에프. 호프만-라 로슈 아게 | 암 질환 조절 항체 |
| WO2008058381A1 (en) * | 2006-11-13 | 2008-05-22 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US20080206133A1 (en) * | 2007-01-23 | 2008-08-28 | Young David S F | Cancerous Disease Modifying Antibodies |
| US8003761B2 (en) | 2007-01-23 | 2011-08-23 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
| KR20090114454A (ko) * | 2007-03-26 | 2009-11-03 | 에프. 호프만-라 로슈 아게 | 하이브리도마 세포주 ａｒ５１ａ６３０.３ 에 의해 생성된 암 질환 조절 항체 ０１０２０７－０１. |
| SI2620451T1 (sl) | 2007-04-05 | 2017-01-31 | Morphotek, Inc. | Metode za zaviranje vezave endosialina na ligande |
| WO2009009203A2 (en) * | 2007-04-19 | 2009-01-15 | The Regents Of The University Of Michigan | Dendrimer based compositions and methods of using the same |
| CN101688183A (zh) * | 2007-05-07 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | 减轻癌性疾病的抗体 |
| US8916135B2 (en) * | 2007-08-22 | 2014-12-23 | Colorado School Of Mines | Lanthanide nanoparticle conjugates and uses thereof |
| JP2010540681A (ja) * | 2007-10-08 | 2010-12-24 | クインテッセンス バイオサイエンシズ，インコーポレーテッド | リボヌクレアーゼに基づく治療のための組成物及び方法 |
| US20090191197A1 (en) * | 2008-01-28 | 2009-07-30 | Young David S F | Cancerous disease modifying antibodies |
| WO2009151687A2 (en) | 2008-03-12 | 2009-12-17 | The Regents Of The University Of Michigan | Dendrimer conjugates |
| WO2009124381A1 (en) * | 2008-04-10 | 2009-10-15 | F. Hoffmann-La Roche Ag | An anti-cancer cytotoxic monoclonal antibody |
| JP2011520923A (ja) * | 2008-05-19 | 2011-07-21 | 武田薬品工業株式会社 | 細胞傷害性抗癌モノクローナル抗体 |
| WO2009155742A1 (zh) * | 2008-06-23 | 2009-12-30 | 广州康采恩医药有限公司 | 一种治疗肺癌的葡聚糖 |
| EP2313437A1 (de) * | 2008-07-17 | 2011-04-27 | Takeda Pharmaceutical Company Limited | Antikörper, die krebserkrankungen modifizieren |
| US8968705B2 (en) | 2008-08-22 | 2015-03-03 | Colorado School Of Mines | Gold/lanthanide nanoparticle conjugates and uses thereof |
| WO2010039861A2 (en) | 2008-09-30 | 2010-04-08 | The Regents Of The University Of Michigan | Dendrimer conjugates |
| EP2334695B1 (de) | 2008-10-01 | 2015-12-23 | Quintessence Biosciences, Inc. | Therapeutische ribonukleasen |
| EP2352490A4 (de) | 2008-10-09 | 2013-11-20 | Univ Northeastern | Selbstanordnende polymere multifunktionsnanosysteme |
| WO2010054321A2 (en) | 2008-11-07 | 2010-05-14 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
| WO2011004899A1 (en) | 2009-07-06 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Cancerous disease modifying antibodies |
| WO2011059609A2 (en) | 2009-10-13 | 2011-05-19 | The Regents Of The University Of Michigan | Dendrimer compositions and methods of synthesis |
| WO2011059586A2 (en) | 2009-10-30 | 2011-05-19 | The Regents Of The University Of Michigan | Multifunctional small molecules |
| US20110201076A1 (en) | 2010-01-22 | 2011-08-18 | Colorado School Of Mines | Harvesting micro algae |
| WO2013085718A1 (en) | 2011-12-08 | 2013-06-13 | The Regents Of The University Of Michigan | Multifunctional small molecules |
| CN109893648A (zh) | 2013-06-28 | 2019-06-18 | 奥克兰联合服务有限公司 | 氨基酸缀合物和肽缀合物及缀合方法 |
| BR112017013574A2 (pt) | 2014-12-23 | 2018-03-06 | Verdon Daniel | conjugados de aminoácido e peptídeo e usos dos mesmos |
| SG11201807036QA (en) | 2016-02-26 | 2018-09-27 | Auckland Uniservices Ltd | Amino acid and peptide conjugates and conjugation process |
| EP3571508B8 (de) | 2017-01-18 | 2023-05-24 | SRI International | Nachweis von krebsstammzellen unter verwendung eines glycan-biomarkers |
| US10975164B2 (en) | 2018-02-26 | 2021-04-13 | Emory University | Antibodies useful for detection of human carcinoma antigen |
| JP7406784B2 (ja) * | 2019-04-17 | 2023-12-28 | 国立大学法人金沢大学 | 卵巣癌の検出方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3867363A (en) * | 1970-06-01 | 1975-02-18 | Hans John Hansen | Carcinoembryonic antigens |
| US4180499A (en) * | 1971-01-27 | 1979-12-25 | Hoffmann-La Roche Inc. | Carcinoembryonic antigens |
| US3956258A (en) * | 1972-05-12 | 1976-05-11 | Hoffmann-La Roche Inc. | Carcinoembryonic antigens |
| US3967638A (en) * | 1975-08-06 | 1976-07-06 | Desalination Systems, Inc. | Combination faucet and air gap |
| US4086217A (en) * | 1976-03-03 | 1978-04-25 | Hoffmann-La Roche Inc. | Carcinoembryonic antigens |
| USRE32417E (en) * | 1979-10-29 | 1987-05-12 | Summa Medical Corporation | Radiolabeled antibody to anti-tumor associated antigen and process |
| US4713352A (en) * | 1981-08-31 | 1987-12-15 | Sloan-Kettering Institute For Cancer Reseach | Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma |
| US4939240A (en) * | 1983-03-04 | 1990-07-03 | Health Research, Inc. | Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy |
| IT1174800B (it) * | 1983-11-21 | 1987-07-01 | Alberto Bartorelli | Metodo per la determinazione di immunoglobuline umane specifiche per gli antigeni dei carcinomi umani e sua utilizzazione nella sierodiognosi di forme primitive tumorali |
| JPS60190721A (ja) * | 1984-03-12 | 1985-09-28 | Kyowa Hakko Kogyo Co Ltd | 抗腫瘍特異的単クロ−ン性抗体の製造法 |
| SE468231B (sv) * | 1984-05-18 | 1992-11-23 | Kabi Pharmacia Ab | Foerfarande foer att paavisa smaacelligt lungcarcinomantigen och anvaendning av antikroppar mot fukosylsialosylgangliotetraos foer framstaellning av komposition foer behandling eller in vivo/ diagnos |
| US4708930A (en) * | 1984-11-09 | 1987-11-24 | Coulter Corporation | Monoclonal antibody to a human carcinoma tumor associated antigen |
| US5019497A (en) * | 1984-11-09 | 1991-05-28 | Lennart Olsson | Human squamous lung carcinoma cell specific antigens and antibodies |
| US4628032A (en) * | 1984-12-05 | 1986-12-09 | The Salk Institute For Biological Studies | Monoclonal antibody specific for a mammary tumor cytoplasmic antigen |
| US4918164A (en) * | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
| US4743543A (en) * | 1985-09-09 | 1988-05-10 | Coulter Corporation | Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample |
| JPS6319561A (ja) * | 1986-07-11 | 1988-01-27 | Kyowa Hakko Kogyo Co Ltd | 抗ヒト肺癌単クロ−ン性抗体 |
| US5030621A (en) * | 1987-04-23 | 1991-07-09 | Bystryn Jean Claude | Shed melanoma antigen compositions |
| US4921790A (en) * | 1987-04-24 | 1990-05-01 | Research Corporation | Tumor specific assay for CA125 ovarian cancer antigen |
| US4837171A (en) * | 1987-07-02 | 1989-06-06 | The General Hospital Corporation | Anti-epiglycanin monoclonal antibodies |
| US4963484A (en) * | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
| US5053489A (en) * | 1988-01-29 | 1991-10-01 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
| JPH03503120A (ja) * | 1988-02-08 | 1991-07-18 | ジョン ミュア キャンサー アンド エージング インスティチュート ディビジョン オブ ジョン ミュア メモリアル ホスピタル | ヒトのガン細胞における新規なムチン様糖蛋白質表面抗原に特異的なモノクローナル抗体 |
| US4914021A (en) * | 1988-03-04 | 1990-04-03 | New England Deaconess Hospital Corporation | Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses |
| US4921789A (en) * | 1988-04-20 | 1990-05-01 | New England Deaconess Hospital Corporation | Marker for colorectal carcinoma and methods of detecting the same |
| US5118611A (en) * | 1988-07-25 | 1992-06-02 | Adeza Biomedical Corporation | Adenocarcinoma antigen binding methods and reagents |
| US5077220A (en) * | 1988-08-26 | 1991-12-31 | John Muir Cancer & Aging Institute | Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells |
| EP0370768A3 (de) * | 1988-11-22 | 1990-09-26 | Taisho Pharmaceutical Co. Ltd | Monoklonaler Antikörper gegen das für Schilddrüsenkarzinom spezifische Antigen |
| AU4668889A (en) * | 1988-11-23 | 1990-06-12 | The Administrators Of The Tulane Eductional Fund | Monoclonal antibodies specific for tumor antigens |
| FR2640511B1 (fr) * | 1988-12-15 | 1993-04-23 | Merieux Inst | Medicaments pour le traitement ou la prevention par immunisation passive de l'infection par le virus hiv et procede de preparation |
| US5268308A (en) * | 1989-04-11 | 1993-12-07 | Howard University | Immunoassay for pyridostigmine |
| EP0394510A1 (de) * | 1989-04-24 | 1990-10-31 | Mochida Pharmaceutical Co., Ltd. | Verfahren zur Bestimmung eines tumorassozierten Antigens in winzigen Mengen von Brustwarzen-Ausfluss und Vorrichtung für eine solche Bestimmung |
| WO1990014433A1 (en) * | 1989-05-24 | 1990-11-29 | The University Of Sydney | Monoclonal antibodies which recognise malignant cells from bladder carcinomas |
| US5110911A (en) * | 1989-11-02 | 1992-05-05 | Biomira, Inc. | Human tumor-associated thomsen-friedenreich antigen |
-
1994
- 1994-02-07 US US08/192,840 patent/US5545532A/en not_active Expired - Lifetime
- 1994-02-07 JP JP51829994A patent/JP4122050B2/ja not_active Expired - Fee Related
- 1994-02-07 CA CA002154266A patent/CA2154266A1/en not_active Abandoned
- 1994-02-07 AU AU61024/94A patent/AU6102494A/en not_active Abandoned
- 1994-02-07 DE DE69432926T patent/DE69432926T2/de not_active Expired - Fee Related
- 1994-02-07 EP EP94907439A patent/EP0686260B1/de not_active Expired - Lifetime
- 1994-02-07 WO PCT/US1994/001379 patent/WO1994018562A1/en active IP Right Grant
- 1994-02-07 AT AT94907439T patent/ATE244888T1/de not_active IP Right Cessation
-
1995
- 1995-06-06 US US08/484,061 patent/US5808005A/en not_active Expired - Fee Related
- 1995-06-06 US US08/468,276 patent/US5693763A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US5808005A (en) | 1998-09-15 |
| EP0686260A4 (de) | 1997-06-18 |
| EP0686260B1 (de) | 2003-07-09 |
| JP4122050B2 (ja) | 2008-07-23 |
| WO1994018562A1 (en) | 1994-08-18 |
| DE69432926T2 (de) | 2004-05-13 |
| CA2154266A1 (en) | 1994-08-18 |
| DE69432926D1 (de) | 2003-08-14 |
| US5545532A (en) | 1996-08-13 |
| US5693763A (en) | 1997-12-02 |
| AU6102494A (en) | 1994-08-29 |
| JPH08506815A (ja) | 1996-07-23 |
| EP0686260A1 (de) | 1995-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69432926D1 (de) | Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy | |
| EP0458878A4 (en) | Novel monoclonal antibody to novel antigen associated with human tumors | |
| HUT42637A (en) | Monoclonic antibodies and antigens for treating human, non-little-cellular carcinomas of lung | |
| EP0536275A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
| CA2033640A1 (en) | Vaccines against cancer and infectious diseases | |
| NO874796D0 (no) | Hybridomcellelinjer som produserer monoklonale antistoffer som reagerer med mucinepitoper. | |
| ES8609731A1 (es) | Un metodo para diagnosticar una condicion neoplastica en un hospedante mamifero | |
| GB2186885B (en) | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas | |
| IE880976L (en) | Human tumour-associated antigen | |
| ES8608685A1 (es) | Procedimiento de preparar anticuerpos monoclonales y metodo de preparar reactivos para detectar canceres | |
| ES2012997A6 (es) | Un procedimiento para la obtencion de una linea de celulas hibridas que producen un anticuerpo monoclonal. | |
| ES8707863A1 (es) | Un procedimiento para producir un anticuerpo monoclonal para carcinoma de pulmon humano de celulas no pequenas. | |
| ZA884777B (en) | Antigen recognized by mca 16 88 | |
| EP0162825A3 (en) | The use of a specific carcinom associated antigen (hapten), fucosylsialosylgangliotetraose (fuc-gm1) in diagnostic or therapeutic procedures related to human lung cancer (small cell carcinomas) | |
| KR880001703A (ko) | 주혈 흡충증에 유용한 능동 면역성분, 그의 면역성 조성물 및 그 제조방법 | |
| DE3570677D1 (en) | Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation | |
| EP0537168A4 (en) | Ctaa 28a32, the antigen recognized by mca 28a32 | |
| AU7144787A (en) | Tumor-associated antigen (mol wt 68,000-48000; 40,000-80000; 28000-32000; 16000-19000) | |
| Ishida et al. | Related Glycoproteins from Normal Secretory and Malignant Breast Cells: Purification and Initial Comparative Characterizations | |
| EP0235817A3 (de) | Monoklonaler Antikörper gegen menschlichen Magenkrebs | |
| DK182188A (da) | Humant tumorassocieret antigen | |
| NO914094L (no) | Nytt monoklonalt antistoff mot nytt antigen forbundet medhumantumorer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |